Praxis Precision Medicines, Inc.
The Patient Programming/Ambassador Manager for ulixacaltamide will own the strategy, planning, and execution of patient-focused programs and ambassador initiatives that bring the patient perspective into Praxis' commercial organization. This role involves building meaningful relationships with patients and caregivers, translating their experiences into impactful programming, and ensuring the patient voice is represented across the brand. The position requires cross-functional collaboration, budget management, and compliance oversight to support people living with essential tremor throughout their treatment journey.
Praxis Precision Medicines is a fully integrated, leading CNS precision neuroscience biopharmaceutical company that translates insights from genetic epilepsies into therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. The company advances a diversified pipeline across epilepsy and movement disorders using two proprietary platforms: Cerebrum™ (small molecules) and Solidus™ (antisense oligonucleotides). Guided by its DARE FOR MORE® philosophy, Praxis applies human genetics, translational science, and patient-guided development to deliver precision therapies for patients with complex brain disorders.
Praxis Precision Medicines, Inc. (PRAX) Gains Analyst Confidence With Ulixacaltamide
3 weeks ago
Biotech Praxis gives 2,931 stock units to 14 new employees
1 week ago
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1 week ago
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Praxis Precision Medicines, Inc..
3,826 Shares in Praxis Precision Medicines, Inc. $PRAX Purchased by ProShare Advisors LLC
2 weeks ago